RxDoctor Payments Data

Paul Kolarsick, MD

Colon & Rectal Surgery · Eatontown, NJNPI 1730526070

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Intuitive Surgical at 49.8% of the total. Reporting peaked in 2019 at $2,332 and has fallen 63.6% since, to $849 in 2025.

$6,110in general payments, 2019–2025

Across 46 payments — averaging $132.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • THD America, Inc.$749
  • Davol Inc.$700
  • Medtronic$324
  • Integra Lifesciences Corporation$312
  • Johnson & Johnson$287
  • plus $699 from 7 others

What the payments were for

  • Travel & lodging$1,57026%
  • Food & beverage$3,52458%
  • Education$1,00016%
  • Gifts$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,110 in reported general payments places this provider in the 75th percentile of 86 colon & rectal surgery providers in New Jersey.

See all colon & rectal surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$75,770
Medicare patients
128
Services billed
424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin Sulfate11$57

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →